Akero Therapeutics Reports 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics, Inc. (NASDAQ:AKRO) reported a 36-week analysis of its 96-week Phase 2b SYMMETRY study. The study evaluates the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH). The results showed a trend on fibrosis improvement and statistically significant results for NASH resolution, markers of liver injury and fibrosis, insulin sensitization and lip.
October 10, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akero Therapeutics' 36-week analysis of its Phase 2b SYMMETRY study showed positive results, which could potentially boost investor confidence in the company's lead product candidate, efruxifermin (EFX).
The positive results from the 36-week analysis of the Phase 2b SYMMETRY study indicate that Akero Therapeutics' lead product candidate, efruxifermin (EFX), is effective in treating patients with compensated cirrhosis due to NASH. This could potentially boost investor confidence in the company and its product, leading to a potential increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100